Germany’s Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using genetic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.